This Study Investigates the Impact of Single Nucleotide Polymorphisms in Genes Involved in the Pharmacokinetics and Toxicity of Doxorubicin (DOX) in Egyptian Female Patients with Breast Cancer. It Also Aims to Explore the Association of Pretreatment Neutrophil to Lymphocyte Ratio to PCR

Plain-language summary

This study investigates the role of single nucleotide polymorphisms (genetic variations) in genes linked to the effect and side effects of the drug Doxorubicin in Egyptian women with breast cancer. It also looked at the relationship between the pretreatment neutrophil-to-lymphocyte ratio and treatment response. Women aged 18 and older took part. It was carried out as a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Menoufia University

Start date

10/1/2021

Estimated completion

11/1/2023

Countries

Egypt

Related genes

Locations

• Shibīn al Kawm, Egypt

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Females aged ≥ 18 years
* Performance status 0 or 1
* No contraindication to chemotherapy
* Adequate bone marrow
* Adequate hepatic function
* Adequate renal function

Exclusion Criteria:

* Poorly controlled diabetes mellitus
* Ischemic heart disease
* Uncontrolled hypertension
* Active infections
* Baseline ejection fraction \< 50%
* Performance status ≥ 2
* Pregnancy Lactation, bilateral breast cancer, male patients, primary surgery, distant metastases, other malignancies, inflammations, hematological disorders, autoimmune diseases, and patients taking non-steroidal anti-inflammatory drugs (NSAIDs), steroidal and antibiotic therapy.